Tobias Tullberg Appointed New CEO of Monivent AB
Monivent AB has appointed Tobias Tullberg as its new CEO, effective January 4, 2027. The company is transitioning into a commercial phase with plans for the European launch of its Neo100 product.
Monivent AB has appointed Tobias Tullberg as the company's new Chief Executive Officer. Tullberg will assume the role on January 4, 2027, as the company prepares to shift from its development and regulatory phase into commercialization.
Monivent recently announced progress toward Medical Device Regulation (MDR) approval, which is expected to clear the path for the European launch of its Neo100 product in partnership with Dräger. Tullberg's appointment aligns with this strategic move towards market entry.
Current CEO and co-founder Maria Lindqvist will remain with Monivent in a newly created role. She will focus specifically on product development and clinical collaborations, ensuring continuity and leveraging her expertise in these critical areas.
The company's transition to a commercial phase and the upcoming product launch represent significant milestones. Tullberg is expected to lead Monivent through this new chapter of growth and market expansion.